---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-26-000031"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:45:56.704956+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LivaNova Q1 revenue $362.3M (+14.3% YoY); raises FY2026 guidance; FDA PMA for aura6000 OSA system

## Summary
- Q1 revenue $362.3M (+14.3% reported, +11.1% CC); GAAP EPS $0.40, adjusted EPS $0.98.
- Raised FY2026 constant-currency revenue growth guidance to 7.0%-8.0% (up 100bps); adjusted EPS guidance raised to $4.20-$4.30.
- Received FDA PMA for aura6000 HGNS system for moderate-to-severe OSA; no CCC contraindication or pre-implant DISE required.
- Published 12-month OSPREY trial results in Annals of Internal Medicine; demonstrated clinically significant responses.
- Q1 adjusted free cash flow $3.8M; maintained FY2026 adjusted FCF guidance $160M-$180M.

## SEC filing metadata
- accession: 0001639691-26-000031
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969126000031/0001639691-26-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969126000031/livn-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-26-000031
- JSON: https://secwatch.observer/filing/0001639691-26-000031.json
- Plain text: https://secwatch.observer/filing/0001639691-26-000031.txt

## Source-grounded claims
- claim_id: 44866422ef6091af7ff3b2a4d1d6945b31accfe3
  claim: LivaNova PLC reported the quarter ended March 31, 2026 results: revenue $362.3 million, EPS $0.40. Guidance raised.
  evidence_excerpt: First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period • First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98
  evidence_url: https://www.sec.gov/Archives/edgar/data/1639691/000163969126000031/0001639691-26-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.